Investor Relations

Corporate Profile

Axcella is a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators (EMMs) to pioneer a new approach for treating complex diseases and improving health. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates for non-alcoholic steatohepatitis (NASH) and the reduction in risk of overt hepatic encephalopathy (OHE) recurrence.

Share Price

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Presentation, Events & News

Stock Information

Historic Price

Learn about the longer term performance of Axcella’s shares

Financials & Filings

SEC Filings

Review Axcella’s historic filings with the U.S. Securities and Exchange Comission

Quarterly Results

View our financial results press releases and quarterly SEC filings

Corporate Governance